The team will present its device and research findings at the American Chemical Society’s fall meeting, according to an Aug. 19 news release from the organization.
The device is called an electrochemical capillary-driven immunoassay and screens for biomarker proteins previously correlated with heart failure, Galectin-3 and S100A7, from a drop of saliva.
In collaboration with Griffith University in Queensland, Australia, researchers are set to test the device in a human trial at the university, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
